KR20170034949A - 야누스 키나제 (jak) 억제제 투여요법 - Google Patents

야누스 키나제 (jak) 억제제 투여요법 Download PDF

Info

Publication number
KR20170034949A
KR20170034949A KR1020177007913A KR20177007913A KR20170034949A KR 20170034949 A KR20170034949 A KR 20170034949A KR 1020177007913 A KR1020177007913 A KR 1020177007913A KR 20177007913 A KR20177007913 A KR 20177007913A KR 20170034949 A KR20170034949 A KR 20170034949A
Authority
KR
South Korea
Prior art keywords
administration
days
compound
dose
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177007913A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 제이. 곤잘레스
샐리 비. 코스그루브
필리스 비. 말파스
미카엘 롤프 스테게만
웬디 터너 콜라드
Original Assignee
조에티스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170034949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 조에티스 엘엘씨 filed Critical 조에티스 엘엘씨
Publication of KR20170034949A publication Critical patent/KR20170034949A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020177007913A 2012-07-20 2013-07-18 야누스 키나제 (jak) 억제제 투여요법 Ceased KR20170034949A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157001085A Division KR20150028299A (ko) 2012-07-20 2013-07-18 야누스 키나제 (jak) 억제제 투여요법

Publications (1)

Publication Number Publication Date
KR20170034949A true KR20170034949A (ko) 2017-03-29

Family

ID=48901189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177007913A Ceased KR20170034949A (ko) 2012-07-20 2013-07-18 야누스 키나제 (jak) 억제제 투여요법
KR1020157001085A Ceased KR20150028299A (ko) 2012-07-20 2013-07-18 야누스 키나제 (jak) 억제제 투여요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157001085A Ceased KR20150028299A (ko) 2012-07-20 2013-07-18 야누스 키나제 (jak) 억제제 투여요법

Country Status (25)

Country Link
US (1) US9522151B2 (cg-RX-API-DMAC10.html)
EP (1) EP2874630B1 (cg-RX-API-DMAC10.html)
JP (2) JP6022063B2 (cg-RX-API-DMAC10.html)
KR (2) KR20170034949A (cg-RX-API-DMAC10.html)
CN (2) CN108354938A (cg-RX-API-DMAC10.html)
AU (1) AU2013292547B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015000808A2 (cg-RX-API-DMAC10.html)
CA (1) CA2878867C (cg-RX-API-DMAC10.html)
CY (1) CY1121436T1 (cg-RX-API-DMAC10.html)
DK (1) DK2874630T3 (cg-RX-API-DMAC10.html)
ES (1) ES2707627T3 (cg-RX-API-DMAC10.html)
HK (2) HK1209314A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20182088T1 (cg-RX-API-DMAC10.html)
HU (1) HUE042771T2 (cg-RX-API-DMAC10.html)
IN (1) IN2015DN00370A (cg-RX-API-DMAC10.html)
LT (1) LT2874630T (cg-RX-API-DMAC10.html)
MX (1) MX360857B (cg-RX-API-DMAC10.html)
NZ (1) NZ703152A (cg-RX-API-DMAC10.html)
PL (1) PL2874630T3 (cg-RX-API-DMAC10.html)
PT (1) PT2874630T (cg-RX-API-DMAC10.html)
RS (1) RS58242B1 (cg-RX-API-DMAC10.html)
SI (1) SI2874630T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900044T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014015107A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201500134B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
CA3303899A1 (en) * 2021-03-16 2026-05-13 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
AU2022263067A1 (en) * 2021-04-22 2023-11-02 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina

Also Published As

Publication number Publication date
WO2014015107A1 (en) 2014-01-23
ES2707627T3 (es) 2019-04-04
MX2015000871A (es) 2015-05-07
BR112015000808A2 (pt) 2017-06-27
CN104470525A (zh) 2015-03-25
HRP20182088T1 (hr) 2019-02-08
RS58242B1 (sr) 2019-03-29
HK1252083A1 (zh) 2019-05-17
HK1209314A1 (en) 2016-04-01
EP2874630B1 (en) 2018-12-05
JP6022063B2 (ja) 2016-11-09
IN2015DN00370A (cg-RX-API-DMAC10.html) 2015-06-12
CA2878867C (en) 2018-01-09
SMT201900044T1 (it) 2019-02-28
CY1121436T1 (el) 2020-05-29
PT2874630T (pt) 2019-01-31
LT2874630T (lt) 2019-02-11
CN108354938A (zh) 2018-08-03
US20150126535A1 (en) 2015-05-07
EP2874630A1 (en) 2015-05-27
AU2013292547A1 (en) 2015-01-22
SI2874630T1 (sl) 2019-04-30
KR20150028299A (ko) 2015-03-13
JP2017019816A (ja) 2017-01-26
NZ703152A (en) 2016-03-31
US9522151B2 (en) 2016-12-20
CA2878867A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
PL2874630T3 (pl) 2019-04-30
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
DK2874630T3 (en) 2019-01-28
MX360857B (es) 2018-11-20

Similar Documents

Publication Publication Date Title
KR20150028299A (ko) 야누스 키나제 (jak) 억제제 투여요법
JP2020079243A (ja) PI3Kインヒビターとc−Metインヒビターの組み合わせ
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
Urbanova et al. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs
JP7640033B2 (ja) ピリド[1,2-a]ピリミジノン類似体の使用
US20200397787A1 (en) Treatment of hand eczema
KR20240009964A (ko) 결절성 양진 치료를 위한 jak1 경로 억제제
US20260069578A1 (en) Treatment of neutrophilic dermatoses
EP4282866A1 (en) Use of pyrido[1,2-a]pyrimidone analogue
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
CN116744923B (zh) 普利多匹定及类似物用于治疗rett综合征的用途
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
TWI843217B (zh) 一種藥物組合及其應用
HK40115079A (en) Methods, dosage regimens, and compositions for treating hidradenitis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170322

Application number text: 1020157001085

Filing date: 20150115

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180831

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I